Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442460 | 0.97 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL8442929 | 0.97 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL106520 | 0.97 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL23269642 | 0.95 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6601123 | 0.95 | ALDH1A1 (0.53) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| Hydrochloric Acid SCHEMBL23123299 | 0.95 | ALDH1A1 (0.53) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL4400116 | 0.94 | ALDH1A1 (0.52) | L3MBTL3L3MBTL1ALDH1A1MBTD1TP53BP1 | |
| SCHEMBL23815785 | 0.93 | ALDH1A1 (0.52) | L3MBTL3L3MBTL1ALDH1A1MBTD1TP53BP1 | |
| SCHEMBL17695417 | 0.91 | ALDH1A1 (0.50) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL15188806 | 0.91 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| EP-4279486-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | Guangzhou Salustier Biosciences Co., Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11656548-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, mask blank with resist film, method for producing photomask, and method for manufacturing electronic device | FUJIFILM CORPORATION (JP) | 2023-05-23 | — | — | US | disclosed |
| WO-2023083373-A1 | COMPOUND USED AS SRC INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006090915-A1 | PYRIDYL ACETIC ACID COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | L3MBTL3 515/4885L3MBTL1 456/4885ALDH1A1 1155/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | L3MBTL3 1287/4885L3MBTL1 1000/4885ALDH1A1 3284/4885 |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | L3MBTL3 2896/4885L3MBTL1 2633/4885ALDH1A1 1501/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 2301/4885L3MBTL1 2500/4885ALDH1A1 2742/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | L3MBTL3 1355/4885L3MBTL1 826/4885ALDH1A1 3889/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | L3MBTL3 914/4885L3MBTL1 864/4885ALDH1A1 299/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | L3MBTL3 2437/4885L3MBTL1 2150/4885ALDH1A1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.